Abeona outlines mid-2027 start for ABO-801 Phase III as it targets >$750M peak annual revenue potential (NASDAQ:ABEO)
· seekingalpha.com
Abeona Therapeutics Q3 2026 earnings: ZEVASKYN revenue grew 18%, ABO-801 adds upside, but timing and regulatory risks remain.
Earnings Call Insights Abeona outlines mid-2027 start for ABO-801 Phase III as it targets >$750M peak annual revenue potential Nov 09, 2026, 3:32 PM ET Abeona T...